Company news

Intelligent Bio Solutions Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Intelligent Bio Solutions Expands U.S. Forensic Market Presence, Seeks FDA Clearance for Breakthrough Fingerprint Drug Testing

June 11, 2025

Intelligent Bio Solutions to Showcase Fingerprint Drug Testing at RISE25 Conference from May 28-31, Supporting Innovation in U.S. Forensic Drug Testing

May 22, 2025

Intelligent Bio Solutions Showcases Rapid, Non-Invasive Drug Testing Capabilities in Remote Queensland Workforce Deployment

May 19, 2025

Intelligent Bio Solutions Accelerates Global Adoption of Fingerprint Drug Testing

May 15, 2025

Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements

May 13, 2025

Intelligent Bio Solutions Drives Global Growth Through Multilingual Digital Expansion

May 6, 2025

Intelligent Bio Solutions Expands Global Reach with Latin American Spanish Language Integration into Drug Screening System

April 22, 2025

Intelligent Bio Solutions Expands Middle East Market Reach with Arabic Integration in Drug Screening System

March 31, 2025

Intelligent Bio Solutions to Highlight Proprietary Drug Testing Technology at 2025 NDASA Conference and Trade Show

March 28, 2025

Intelligent Bio Solutions Highlights Continued Expansion with Strategic Partnership in Spain and Andorra

March 27, 2025

Intelligent Bio Solutions Secures Key U.S. Patent, Strengthening IP Protection Ahead of Planned 2025 Market Entry

March 26, 2025

Intelligent Bio Solutions’ FDA Clearance Process Remains on Track for 2025 U.S. Launch

March 25, 2025

Intelligent Bio Solutions to Expand U.S. IP Portfolio with Expected Patent Grant

March 20, 2025

Intelligent Bio Solutions to Participate in the iAccess Virtual Best Ideas Spring Conference on March 25th and 26th

March 11, 2025

Intelligent Bio Solutions Inc. Announces Closing of $3.0 Million Public Offering of Common Stock and Full Exercise of the Underwriter’s Option to Purchase Additional Shares of Common Stock

February 21, 2025

Intelligent Bio Solutions Inc. Announces Pricing of $2.6 Million Public Offering of Common Stock

February 20, 2025

Intelligent Bio Solutions Inc. Announces Proposed Public Offering of Common Stock

February 19, 2025

Intelligent Bio Solutions Announces Fiscal Q2 2025 Financial Results and Key Operational Achievements

February 12, 2025

Intelligent Bio Solutions Releases Shareholder Letter Detailing 2024 Growth and 2025 U.S. Expansion Strategy

February 9, 2025

Intelligent Bio Solutions Expands Global Reach with Multilingual Drug Screening System Upgrade

January 30, 2025

Intelligent Bio Solutions Partners with IVY Diagnostics to Expand in Europe’s $3.6 Billion Drug Screening Market and in Middle Eastern Regions

January 27, 2025

Intelligent Bio Solutions Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology

December 17, 2024

Intelligent Bio Solutions Achieves 94.1% Accuracy in Method Comparison Study, Following Positive PK Study Results

November 25, 2024

Intelligent Bio Solutions Announces Positive Results of PK Study, a Key Milestone on Path to FDA 510(k) Submission

November 12, 2024

Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights

November 6, 2024

Intelligent Bio Solutions Partners with B2i Digital to Amplify Investor Outreach

October 30, 2024

Intelligent Bio Solutions Announces Preliminary Unaudited Fiscal 2025 First Quarter Revenue Results

October 28, 2024

Intelligent Bio Solutions Announces Adoption of its Non-Invasive Drug Screening Solution by Global Engineering Leader, Pyrotek

October 13, 2024

Intelligent Bio Solutions Partners with Spirit Group as Australian Distributor, Expanding Community Impact with Intelligent Fingerprinting Drug Testing Solution

October 8, 2024

Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission

September 26, 2024

Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights

September 18, 2024

Intelligent Bio Solutions Inc. Announces Preliminary Full Fiscal Year 2024 Revenue Growth of 148% Year-Over-Year

September 8, 2024

Intelligent Bio Solutions Inc. Announces Progress Toward Completion of Clinical Study Plan Required for FDA 510(k) Submission

September 4, 2024

Intelligent Bio Solutions Inc. Achieves Major Milestone with Over 1,000 Installed Intelligent Fingerprinting Drug Screening Readers as of June 30, 2024

August 20, 2024

Intelligent Bio Solutions Partners with CenExel to Conduct Clinical Study as Part of FDA 510(k) Pathway

July 31, 2024

Intelligent Bio Solutions Inc. Announces QabasTech as Exclusive Distributor in Saudi Arabia

July 23, 2024

Intelligent Bio Solutions Inc. Advances on FDA 510(k) Pathway with Biocompatibility Study Success

July 17, 2024

Intelligent Bio Solutions Strengthens UK Market Position with Addition of Key Manufacturing Accounts

July 8, 2024

Intelligent Bio Solutions Completes In-Clinic Portion of Pharmacokinetic (PK) Study Part of 510(k) Pathway for Approval & Commences Review of Results

June 27, 2024

Intelligent Bio Solutions Broadens UK Customer Base by Securing Two Key Accounts with Over 70 Locations and Over 15,000 Employees in the Warehouse and Logistics Sector

June 19, 2024

Intelligent Bio Solutions Begins Subject Dosing and Sampling for FDA 510(k) Pharmacokinetic (PK) Study for its Intelligent Fingerprinting Drug Screening Technology

June 17, 2024

Intelligent Bio Solutions Implements Strategic Reorganization Plan to Support Global Growth Initiatives

June 12, 2024

Intelligent Bio Solutions Inc. Reports Fiscal 2024 Third Quarter and Nine-Month Financial Results and Operational Highlights

May 7, 2024

Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Third Quarter and Nine-Month Revenue Results

April 17, 2024

Intelligent Bio Solutions Announces $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules

March 10, 2024

Intelligent Bio Solutions Partners with Cliantha Research to Conduct Clinical Study as Part of FDA 510(k) Pathway

February 27, 2024

Intelligent Bio Solutions Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement and Confirms Compliance with Minimum Stockholders’ Equity Requirement

February 15, 2024

Intelligent Bio Solutions Inc. Reports Fiscal Second Quarter and Six-Month Financial Results and Operational Highlights

February 8, 2024

Intelligent Bio Solutions Inc. Announces Exercise of Previously Issued Warrants for $1.77 Million in Gross Proceeds

February 4, 2024

Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Second Quarter and Six-Month Revenue Results

February 1, 2024

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 8 decks. Every deck is listed under its year.